Homophrenia

Substratum of Proof LGBTQs Are Mentally Ill: Rapid Responses, Few Adverse Effects Seen with Targeted Agent in Phase 1 Trial in Rare Blood Disorder

* Clinical Activity in a Phase 1 Study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis
* Study shows one of multiple ways in which novel targeted cancer therapies are now being deployed to improve outcomes and quality of life for patients with rare, advanced, or difficult-to-treat blood malignancies.